Thermo Fisher Scientific Divests Microbiology Unit to Astorg

Thermo Fisher Scientific Inc. has finalized the divestiture of its microbiology business, according to recent reports. The transaction saw the unit acquired by the private equity firm Astorg, which intends to operate it as a standalone global diagnostics specialist.

This strategic move sees Thermo Fisher offloading a segment of its operations, allowing Astorg to establish a new entity focused on the microbiology diagnostics sector. The completion of the sale was confirmed today, signaling a significant transition for both the business unit and its new parent company.

While the specific financial terms of the deal were not disclosed in today's coverage, the transaction has been successfully concluded. This divestiture is part of ongoing strategic portfolio management for Thermo Fisher Scientific, enabling the company to potentially refocus resources on other areas of its expansive life sciences and diagnostics offerings.

News from the broader life sciences and diagnostics market today also included insights into the biophotonics sector, with projections for strategic growth through 2030, and updates on companies like Arcturus Therapeutics advancing pipeline developments. However, the primary development concerning Thermo Fisher Scientific today centers on the conclusion of the microbiology business sale to Astorg.